Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Non-small Cell Lung Cancer (NSCLC) Clinical Trial

Official title:

Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06448793
• Other study ID #: CA209-1384
• Status: Not yet recruiting
• Start date: March 1, 2025
• Est. completion date: April 30, 2025

Study information

• Verified date: June 2024
• Source: Bristol-Myers Squibb
• Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com
• Phone: 855-907-3286
• Email: Clinical.Trials[@]bms.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 55
• Est. completion date: April 30, 2025
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients

• Aged =18 years at the time of enrollment in the study

• Resident of the US, Germany, or Japan

• Able to read, speak, and understand English, German or Japanese

• Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)

Physicians

• Resident of the US, Germany, or Japan

• Lung cancer-treating physician specialized in one of the following medical areas:

oncology, pneumonology, thoracic surgery, or radiology

• Treated at least three new patients with resectable NSCLC in the past year

Exclusion Criteria:

Patients

• Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)

• Being diagnosed with another malignancy alongside NSCLC

• Not willing to be audio-recorded during the interview

Physicians

• Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)

• Not willing to be audio-recorded during the interview

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer (NSCLC)

Intervention

Drug:
• Approved Non-small Cell Lung Cancer (NSCLC) therapies
As prescribed by treating physician

Locations

Country	Name	City	State
United Kingdom	Evidera	London

Sponsors (1)

Lead Sponsor	Collaborator
Bristol-Myers Squibb

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Responses to qualitative interview questions	Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.	Day 1
Primary	Patient sociodemographic		Day 1
Primary	Patient clinical characteristics		Day 1

External Links

•   BMS Clinical Trial Information
•   FDA Safety Alerts and Recalls